RESUMEN
There is no definitive approach for assessing mesenteric ischemia and determining the optimal timing for endovascular intervention in the management of spontaneous isolated dissection of the superior mesenteric artery (SISMAD). A 56-year-old male with acute abdominal pain was diagnosed with SISMAD. After evaluating mesenteric ischemia through mesenteric fractional flow reserve (FFR), FFR was 0.72, and the patient was recommended conservative treatment for SISMAD, which involves fasting, total parenteral nutrition, and anticoagulation. The patient's syndrome was relieved after conservative treatment for 14 days without stent implantation. Over the next 5 years, no recurrence of abdominal pain or worsening of SISMAD was observed in the patient. Assessing the severity of mesenteric ischemia can be done through mesenteric FFR. Upon confirmation of the exclusion of risks related to dilatation or rupture of SISMAD aneurysm, an approach in favor of conservative management for SISMAD may indeed be considered pragmatic when the FFR exceeds 0.72.
RESUMEN
The osteoblast-derived paracrine factor osteoprotegerin (OPG) is considered to play a key role in inhibition of osteoclast formation and activity. Recently, raloxifene, a nonsteroidal benzothiophene, was found to exert anti-resorptive effects via modulating OPG expression in osteoblasts. To explore whether raloxifene regulates bone metabolism via an OPG-dependant pathway in vivo, we investigated the effects of raloxifene on bone loss in Opg-deficient mice. The results show that bone mineral density and bone strength are increased in mice deficient for Opg after treatment with raloxifene for 30 days. Histomorphometric analysis shows that raloxifene can increase bone trabecular area and decrease the number of osteoclasts in Opg (-/-) mice. Moreover, raloxifene reduces Rankl transcription and serum level of Rankl, which is dramatically increased in Opg knockout mice. These results suggest that raloxifene-induced inhibition of bone resorption may be independent of Opg pathway in mice.
Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Conservadores de la Densidad Ósea/uso terapéutico , Resorción Ósea/prevención & control , Huesos/efectos de los fármacos , Osteoprotegerina/metabolismo , Clorhidrato de Raloxifeno/farmacología , Clorhidrato de Raloxifeno/uso terapéutico , Animales , Densidad Ósea/efectos de los fármacos , Resorción Ósea/sangre , Resorción Ósea/metabolismo , Resorción Ósea/patología , Huesos/química , Huesos/patología , Recuento de Células , Módulo de Elasticidad , Femenino , Fémur/química , Fémur/efectos de los fármacos , Fémur/patología , Regulación de la Expresión Génica/efectos de los fármacos , Vértebras Lumbares/química , Vértebras Lumbares/efectos de los fármacos , Vértebras Lumbares/patología , Fenómenos Mecánicos , Ratones , Ratones Noqueados , Osteoclastos/efectos de los fármacos , Osteoclastos/patología , Osteoprotegerina/sangre , Osteoprotegerina/genética , Ligando RANK/sangre , Ligando RANK/genética , Ligando RANK/metabolismo , ARN Mensajero/metabolismo , Distribución AleatoriaRESUMEN
OBJECTIVE: To extract volatile oil from Shiquandabu pills and study technological process of its inclusion compound with beta-Cyclodextrin (beta-CD) to improve its stability. METHODS: The study was carried out with steam distillation and orthogonal design. The process conditions were studied by determining the utilization and ratio of oil from Shiquandabu pills volatile oil and extract ratio of in-clusion compound. The most important factor was the ratio of oil to beta-CD. and the inclusion compound was identified by FT-IR spectra and XRD. RESULTS: The optimum preparation conditions for inclusion were best-established as oil: beta-CD was 1:8, the inclusion time and temperature were for 1.0 hours. at 20 degrees C. CONCLUSION: Tne method can be used for increasing volatile oil's stability and its solubility. It is suitable for production of medicinal preparation.